• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Antiobesity Medications: Expert Compares Benefits, Drawback Among Classes

News
Video

Obesity specialist Sandra Christensen, MSN, ARNP, compares the benefits and drawbacks among older antiobesity drugs and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

In a recent interview with Patient Care Online, medical weight management specialist Sandra Christensen, MSN, ARNP, was asked the following question:

What are the benefits and drawbacks to the different classes of antiobesity medications?

Ms Christensen discusses how the different classes of antiobesity medications compare in cost, side effect profiles, and more in the video below.

For a primer on common antiobesity medications, check out part 1 of our interview with Ms Christensen: Antiobesity Medications: Expert Discusses Older, Newer Therapies

Sandra Christensen, MSN, ARNP, is the owner of Integrative Medical Weight Management in Seattle, Washington.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Related Content
American Liver Foundation Announces First Federally-Funded Research on MASLD / image credit American Liver Foundation Lorraine Stiehl

American Liver Foundation Announces First Federally-Funded Research on MASLD

April 26th 2024
Article

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Breathlessness Related to Medical Conditions in Middle-Aged Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Breathlessness Related to Medical Conditions in Middle-Aged Adults: Daily Dose

April 23rd 2024
Article

Your daily dose of the clinical news you may have missed.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Navigating the New Wave of Antiobesity Medications: What Primary Care Clinicians Should Know / Image credit: ©Antonio Diaz/AdobeStock

Navigating the New Wave of Antiobesity Medications: What Primary Care Clinicians Should Know

April 17th 2024
Article

With the rise in demand for newer antiobesity medications, clinicians may face more questions from patients. Here, a primer on the drawbacks and benefits to keep in mind.

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Regulatory Submission / image credit obese man asleep / ©motortion/stock.adobe.com

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission

April 17th 2024
Article

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

© 2024 MJH Life Sciences

All rights reserved.